RxDoctor Payments Data

Caroline Lenaerts

Adult Health · Sacramento, CANPI 1881040970

Payments from drug & device makers

$2,325in general payments, 2019–2025

Across 20 payments — averaging $116.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$437
  • Tandem Diabetes Care, Inc.$381
  • Dexcom, Inc.$369
  • Mannkind Corporation$282
  • BETA Bionics, Inc.$145
  • Sequel Med Tech, LLC$142
  • plus $567 from 5 others

What the payments were for

  • Food & beverage$2,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,325 in reported general payments places this provider in the 85th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$65,760
Medicare patients
217
Services billed
966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$102,350
TrulicityDulaglutide63$61,797
JardianceEmpagliflozin63$59,880
MounjaroTirzepatide53$57,604
Fiasp FlextouchInsulin Aspart (Niacinamide)83$50,447
RybelsusSemaglutide26$32,527
TradjentaLinagliptin24$23,328
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$21,168
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$20,035
Humalog Kwikpen U-200Insulin Lispro11$18,765
JanuviaSitagliptin Phosphate26$18,005
Tresiba Flextouch U-100Insulin Degludec29$15,047
Tresiba Flextouch U-200Insulin Degludec12$14,756
Humalog Kwikpen U-100Insulin Lispro57$11,193
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$8,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$437$138,363116 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$121$124,485133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 785 adult health providers in California.

Other adult health in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →